Webinar: Phase 2 Clinical trial results of the Pan-PPAR Agonist Lanifibranor in NASH patients
In this webinar Prof. Sven Francque will be discussing the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.
Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno